Skip to main content

The Biomarker Company

SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and monitoring of acute medical conditions, such as septic shock, circulatory failure, acute heart failure and acute kidney injury. SphingoTec’s first-in-class tests are made available on its proprietary whole-blood point-of-care Nexus IB10 platform for convenient and rapid testing in near-patient and laboratory settings alongside a broad portfolio of standard-of-care test for acute care. For high throughput testing in central laboratories, SphingoTec is open to partner with global IVD players. 

Our Mission

To improve patient outcomes with innovative diagnostic solutions for acute care and preventive medicine: Actionable insights in real-time.

Certified Quality

SphingoTec is committed to providing products that meet and exceed customer and regulatory requirements.
We produce our products in accordance with EN ISO 13485:2016. 

ISO 13485 Certificate (English)

ISO 13485 Certificate (German)

Nexus Dx

Nexus Dx Inc., a wholly-owned subsidiary of SphingoTec, headquartered in San Diego, CA, USA, is a global provider of a near patient testing system and advanced diagnostic solution. Nexus Dx is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. 

Medicine4Future Initiative

The companies of the Medicine4Future Initiative, SphingoTec GmbH, 4TEEN4 Pharmaceuticals GmbH, Adrenomed AG and Nexus Dx Inc., have the common goal to improve the management of critically ill patients by innovative biomarkers and drug targets. Starting from assay development and growing evidence from large cohort studies, blood biomarkers are associated with relevant patient outcomes in underserved medical conditions. Based on data that prove that a biomarker can reliably monitor disease states and predict outcomes, antibodies are subsequently developed to validate if the biomarker also represents a druggable target. If so, drug candidates are tested in appropriate pre-clinical models and consecutively enter first in-men clinical trials. The long-term vision of Dr. Andreas Bergmann, founder of the Medicine4Future Initiative, is to develop early diagnostics that help prevent manifestation of common diseases.

Bergmann's way

Andreas Bergmann and his team developed a unique way of discovering new biomarker candidates by using blood-based analysis. Learn more about the way to connect diagnostics and therapeutic strategies in critical care.

Play Video